340B Impact: Roche Starts Educating Investors About Discount
Executive Summary
The 340B hospital discount program has a much higher profile in the Rx policy world than it did before the Affordable Care Act was signed into law; now, Roche is starting to highlight the impact of the program to a different audience: its investors.
You may also be interested in...
340B Reform Remains Elusive Even As Spending Increases
Total purchases at 340B prices by 2021 are projected to exceed $23 bil – more than total Medicare Part B drug reimbursement in 2014.
Part B Demo Could Save $2.2 Bil., CBO Says; Blocking It Would Cost Less
CMS’ proposal to test alternate payment methods for Part B drugs could save as much as $2.2 billion over 10 years, the Congressional Budget Office told Congress. However, a bill to block implementation of the program would only cost $395 million for scoring purposes.
340B “Mega-Guidance” Delayed To December (Or Beyond)
HRSA official stresses importance “good faith” by manufacturers and purchasers to assure program integrity while key definitions remain in limbo.